Discontinued — last reported Q4 '17
Indefinite-Lived Research and Development Assets
Viatris Indefinite-Lived Research and Development Assets remained flat by 0.0% to $706.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.2%, from $804.40M to $706.00M. Over 5 years (FY 2020 to FY 2025), Indefinite-Lived Research and Development Assets shows an upward trend with a 54.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
Detailed definition
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Peer comparison
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assetsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $79.80M | $79.80M | $46.50M | $45.70M | $43.80M | $42.50M | $40.20M | $331.10M | $331.30M | $319.60M | $319.40M | $994.10M | $892.10M | $891.60M | $814.20M | $804.40M | $801.90M | $777.80M | $706.00M | $706.00M |
| QoQ Change | — | +0.0% | -41.7% | -1.7% | -4.2% | -3.0% | -5.4% | +723.6% | +0.1% | -3.5% | -0.1% | +211.2% | -10.3% | -0.1% | -8.7% | -1.2% | -0.3% | -3.0% | -9.2% | +0.0% |
| YoY Change | — | — | — | — | -45.1% | -46.7% | -13.5% | +624.5% | +656.4% | +652.0% | +694.5% | +200.2% | +169.3% | +179.0% | +154.9% | -19.1% | -10.1% | -12.8% | -13.3% | -12.2% |
Indefinite-Lived Research and Development Assets at Other Companies
Frequently Asked Questions
- What is Viatris's indefinite-lived research and development assets?
- Viatris (VTRS) reported indefinite-lived research and development assets of $706.00M in Q1 2026.
- How has Viatris's indefinite-lived research and development assets changed year-over-year?
- Viatris's indefinite-lived research and development assets decreased by 12.2% year-over-year, from $804.40M to $706.00M.
- What is the long-term trend for Viatris's indefinite-lived research and development assets?
- Over 5 years (2020 to 2025), Viatris's indefinite-lived research and development assets has grown at a 54.3% compound annual growth rate (CAGR), from $80.70M to $706.00M.
- What does indefinite-lived research and development assets mean?
- The value of ongoing research projects acquired from other companies that are not yet ready for sale.